Related Experiment Videos
Flutamide photosensitivity--residual vitiliginous lesions
J Vilaplana1, C Romaguera, A Azón
1Servei de Dermatologia, Hospital Clínic i Provincial, Facultat de Medicina, Universitat de Barcelona, Spain.
Contact Dermatitis
|March 20, 1998
Summary
Flutamide photosensitivity, a rare side effect in prostate cancer patients, was confirmed via photopatch testing. This finding suggests flutamide should be considered when investigating photosensitive patients.
Area of Science:
- Dermatology
- Oncology
- Photobiology
Background:
- Prostate cancer treatment often involves flutamide.
- Photosensitivity is an adverse drug reaction that can impact patient quality of life.
- Understanding drug-induced photosensitivity is crucial for patient management.
Observation:
- A case of photosensitivity reaction to flutamide was observed in a patient undergoing prostate cancer treatment.
- Photopatch testing with flutamide (10% and 20% in acetone) yielded positive results.
- Control tests were negative, indicating flutamide as the causative agent.
Findings:
- Flutamide can induce photosensitivity, a reaction triggered by ultraviolet (UV) radiation.
- The specific characteristics of flutamide photosensitivity (UV-A vs. UV-B) remain unclear due to limited case reports and varying testing methodologies.
- Photopatch testing is a valuable diagnostic tool for identifying flutamide-induced photosensitivity.
Implications:
- Clinicians should consider flutamide as a potential cause of photosensitivity in patients, particularly those treated for prostate cancer.
- Including flutamide in the diagnostic workup for photosensitive patients may improve diagnosis and management.
- Further research is needed to fully characterize flutamide photosensitivity and optimize diagnostic approaches.